Product Overview

RIBOMUSTIN 25 mg Powder for concentrate for solution for infusion is a vital medication used in the treatment of certain types of cancer.

Developed by Astellas Pharma Europe B.V., it contains Bendamustine Hydrochloride, a potent cytotoxic agent.

This medication is specifically indicated for conditions such as Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin Lymphoma (NHL), and Multiple Myeloma.

It is designed for intravenous administration, requiring professional medical supervision due to its specific handling and administration protocols.

About Ribomustin 25 mg

Ribomustin 25 mg is an alkylating agent, a class of chemotherapy drugs that work by interfering with the DNA of cancer cells, thereby inhibiting their growth and division.

Each vial contains 25 mg of Bendamustine Hydrochloride, prepared as a powder that must be reconstituted and diluted before infusion.

The formulation ensures targeted action against rapidly dividing cancer cells, playing a crucial role in various treatment regimens.

Its application is a critical component of comprehensive cancer care strategies.

Benefits of Ribomustin

• Effective in treating Chronic Lymphocytic Leukemia (CLL) in first-line and relapsed/refractory settings.
• Proven efficacy in specific types of Non-Hodgkin Lymphoma (NHL), particularly indolent forms.
• Utilized in the management of Multiple Myeloma when other therapies are unsuitable.
• Contributes to disease control and improvement in patient outcomes when used appropriately under medical guidance.

How to Use

1. RIBOMUSTIN 25 mg must only be prepared and administered by qualified healthcare professionals.
2. The powder in each vial is reconstituted with sterile water for injection according to manufacturer guidelines to form a concentrate.
3. The concentrate is then further diluted into a suitable infusion solution (e.g., sodium chloride 0.9% or Ringer's lactate).
4. The diluted solution is administered via intravenous infusion over a specified period, as determined by the patient's treatment protocol and medical condition.
5. Dosage and infusion schedule are tailored to individual patient needs, disease type, and stage.

Caution & Warnings

• RIBOMUSTIN 25 mg is a potent chemotherapy agent; it should only be used under the supervision of a physician experienced in cancer chemotherapy.
• Patients must be monitored closely for bone marrow suppression (myelosuppression), including neutropenia, thrombocytopenia, and anemia, which can be severe.
• Risk of infections, including opportunistic infections, is increased; prompt management is crucial.
• Hypersensitivity reactions, including anaphylaxis, can occur; appropriate emergency equipment should be readily available.
• Tumor lysis syndrome (TLS) may occur, especially in patients with high tumor burden; preventative measures and close monitoring are essential.
• Serious skin reactions have been reported; discontinue treatment if severe reactions occur.
• Avoid pregnancy during treatment and for a specified period after due to potential fetal harm. Discuss contraception options with a healthcare provider.
• Lactation should be discontinued during treatment.

Ingredients

Active Ingredient:

• Bendamustine Hydrochloride 25 mg per vial

Excipients:

• Mannitol

Product Details

Form: Powder for concentrate for solution for infusion

Strength: 25 mg per vial

Package Size: 5 vials per pack

Manufacturer: Astellas Pharma Europe B.V.

Administration Route: Intravenous